Financials
Financial year 2025
PHARMUNY from Ellezelles, company number BE0443874077, closed financial year 2025 with a result of € 121,007 after tax. For that financial year PHARMUNY recorded a gross margin of € 416,377 and equity of € 309,069. Compared with financial year 2024, the result moved from € 84,236 to € 121,007. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 22, 2026.
€ 309,069
▲ 20% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 121,007
▲ 44% vs 2024
Profit after tax over the fiscal year.
€ 235,447
▼ 4% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 70,000 paid out
58 % of the profit went to the shareholders, mostly to HCD Management (100 % of the shares). That is where the money ends up.
People and assets in 2025
2.4
▲ 0.3 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 174,083
▲ 17% vs 2024
€ 72,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 9,937
▲ 158% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 339,138
▼ 20% vs 2024
€ 81,277 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.
€ 74,098
▼ 31% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 57,820
▲ 79% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 335,565 | € 378,077 | € 346,176 | € 416,377 | ▲ 20% |
| Profit after taxes | € 93,269 | € 88,983 | € 84,236 | € 121,007 | ▲ 44% |
| Equity | € 224,843 | € 243,826 | € 258,062 | € 309,069 | ▲ 20% |
| Total debts | € 894,262 | € 758,823 | € 704,713 | € 600,562 | ▼ 15% |
| Cash | € 315,019 | € 257,417 | € 246,381 | € 235,447 | ▼ 4% |
| Land & buildings | € 463,963 | € 424,552 | € 391,753 | € 353,955 | ▼ 10% |
| Retained profit | € 163,343 | € 182,326 | € 196,562 | € 247,569 | ▲ 26% |
| Dividend | € 70,000 | € 70,000 | € 70,000 | € 70,000 | |
| Bank debt | € 580,343 | € 500,373 | € 425,357 | € 339,138 | ▼ 20% |
| Balance sheet total | € 1,119,105 | € 1,002,648 | € 962,775 | € 909,631 | ▼ 6% |
| Employees (FTE) | 2.4 | 3 | 2.1 | 2.4 | ▲ 0.3 |
Key figures of PHARMUNY, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PHARMUNY?
What happened at PHARMUNY in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Colette Delvigne stepped down as director. NBB
- BENOIT DESCHAMPS stepped down as director. NBB
- HCD Management SRL stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 121,007 (▲ 44% vs 2024). Source: NBB ↗
- SAMUEL VAN BAEL stepped down as director. NBB
- Colette Delvigne became a director. NBB
- BENOIT DESCHAMPS became a director. NBB
- SAMUEL VAN BAEL became a director. NBB
In short
From € 93,269 profit in 2022 to € 121,007 profit in 2025.
Paid € 138,815 in corporate taxes since 2022.
Best year ever: 2025, with € 121,007 profit.
On average € 173,500 of value added per employee in 2025.
A new publication or filing at PHARMUNY? We notify you, reason included.
Follow PHARMUNYDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of HCD Management comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
PHARMUNYThe shares are held by HCD Management (99.8%).
Directors
According to the 2025 annual accounts
since 2020 · until 2026
since 2020 · until 2026
SAMUEL VAN BAEL
Director
since 2020 · until 2025
since 2020 · until 2026
Shareholders
99.8%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Place 16
7890 Ellezelles
Rue de Renaix 1
7890 Ellezelles
Active since 10 June 1991
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0443.874.077
- VAT number
- BE 0443.874.077
- Registered office
- Place 16, 7890 Ellezelles
- Names & denominations
- PHARMUNY
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 5 April 1991
- Peppol
- Active · Active since 2 Oct 2025
- Activities · NACE
Apothekers
Detailhandel in farmaceutische producten